NDC 0074-2100 Skyrizi

Risankizumab-rzaa Injection Subcutaneous - View Dosage, Usage, Ingredients, Routes, UNII

Product Information

NDC Product Code:
0074-2100
Proprietary Name:
Skyrizi
Non-Proprietary Name: [1]
Risankizumab-rzaa
Substance Name: [2]
Risankizumab
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Dosage Form:
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route(s): [4]
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Labeler Name: [5]
    Abbvie Inc.
    Labeler Code:
    0074
    FDA Application Number: [6]
    BLA761105
    Marketing Category: [8]
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date: [9]
    04-26-2021
    Listing Expiration Date: [11]
    12-31-2025
    Exclude Flag: [12]
    N
    Code Structure:
    Code Navigator:

    Product Packages

    NDC Code 0074-2100-01

    Package Description: 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE

    Price per Unit: $20292.26778 per ML

    NDC Code 0074-2100-70

    Package Description: 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE

    Product Details

    What is NDC 0074-2100?

    The NDC code 0074-2100 is assigned by the FDA to the product Skyrizi which is a human prescription drug product labeled by Abbvie Inc.. The generic name of Skyrizi is risankizumab-rzaa. The product's dosage form is injection and is administered via subcutaneous form. The product is distributed in 2 packages with assigned NDC codes 0074-2100-01 1 syringe in 1 carton / 1 ml in 1 syringe, 0074-2100-70 1 syringe in 1 carton / 1 ml in 1 syringe. This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

    What are the uses for Skyrizi?

    This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

    What are Skyrizi Active Ingredients?

    An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

    What is the NDC to RxNorm Crosswalk for Skyrizi?

    RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
    • RxCUI: 2166136 - risankizumab-rzaa 75 MG in 0.83 mL Prefilled Syringe
    • RxCUI: 2166136 - 0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe
    • RxCUI: 2166136 - risankizumab-rzaa 75 MG per 0.83 ML Prefilled Syringe
    • RxCUI: 2166137 - {2 (0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe) } Pack
    • RxCUI: 2166137 - risankizumab-rzaa 75 MG in 0.83 mL (2) Prefilled Syringe Pack

    Which are the Pharmacologic Classes for Skyrizi?

    A pharmacologic class is a group of drugs that share the same scientifically documented properties. The following is a list of the reported pharmacologic class(es) corresponding to the active ingredients of this product.

    * Please review the disclaimer below.

    Patient Education

    Risankizumab-rzaa Injection


    Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used to treat active psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) in adults. Risankizumab-rzaa injection is also used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults. Risankizumab-rzaa is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
    [Learn More]


    * Please review the disclaimer below.

    Product Footnotes

    [1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

    [2] What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

    [3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

    [4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.

    [5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

    [6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

    [8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

    [9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

    [11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

    [12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".